Vaccinia virus
| Brincidofovir | VACV | Viral DNA polymerase inhibitor | Phase 3 | — | Viral DNA pol | |
| Vidarabine | VACV | — | FDA approved | FDAJapan | — | |
| Adefovir dipivoxil | VACV | Viral DNA chain termination | Approved (other) | Japan | Viral RNA pol | |
| Bleomycin | VACV | Unknown | Preclinical | — | Human LIG1 | |
| Brivudine | VACV | Inhibits viral DNA synthesis | Preclinical | — | Viral DNA pol | |
| Cyclosporine | VACV | Calcineurin inhibitor; allows for inhibition of T cell activation | Preclinical | — | Human CYPs | |
| Ganciclovir | VACV | Viral RNA polymerase inhibitor | Approved (other) | JapanChina | Viral DNA pol | |
| Gefitinib | VACV | EGFR inhibitor | Preclinical | — | Human PTK | |
| Gemcitabine | VACV | Antimetabolite; Nucleoside analog | Preclinical | — | Viral DNA pol | |
| Idoxuridine | VACV | Inhibits viral DNA synthesis | Approved (other) | Japan | Viral DNA pol | |
| Inosine (Inosine pranobex) | VACV | Stimulates cell-mediated immune response | Preclinical | — | Viral DNA pol | |
| JIB-04 | VACV | Human HDAC inhibitor | Preclinical | — | Human HDAC | |
| Lipoic acid | VACV | Enzymatic cofactor | Preclinical | — | Human lipoyltransferase | |
| Niclosamide | VACV | — | Preclinical | — | Human (multiple) | |
| Nitazoxanide | VACV | Pyruvate inhibitor | Preclinical | — | Human pyruvate synthase | |
| Novobiocin | VACV | Bacterial DNA gyrase inhibitor (targeting GyrB) | Preclinical | — | Unknown | |
| Raloxifene | VACV | Selective estrogen receptor modulator | Preclinical | — | Human (multiple) | |
| Trifluridine | VACV | Antimetabolite; Nucleoside analog | Preclinical | — | Viral DNA pol |